Webinar "Multi-Criteria Decision Analysis (MCDA) in Rare Diseases"

Evaluating orphan drugs presents unique challenges: limited clinical data, a high degree of uncertainty, and numerous factors that must be considered in decision-making. Classic health technology assessment models prove inadequate in these settings. Multicriteria decision analysis (MCDA) is becoming increasingly popular in many countries. It allows for the evaluation process to incorporate not only the effectiveness and cost of treatments, but also the severity of the disease, the level of unmet medical need, the presence or absence of alternatives, and the impact on patients' quality of life.

The CIS Orphan Consortium invites you to a webinar dedicated to the application of MCDA in rare diseases. Participants will be able to learn about international experience, practical examples from CIS countries, and participate in a panel discussion on the prospects for implementing this approach in national healthcare systems.

Webinar Program:

1. Differentiated Procedures for Evaluating Orphan Drugs: International Experience
Nuriya Zagitovna Musina, Executive Director of the CIS Orphan Consortium, Director of International Cooperation at NAERES

2. Review of International Multicriteria Decision Analysis (MCDA) Tools
Valeria Aleksandrovna Lemeshko, Association of International Pharmaceutical Manufacturers (AIPM)

3. Experience with MCDA in the Republic of Kazakhstan
Adlet Berikbolovich Tabarov, Deputy Chairman of the Board of the National Scientific Center for Healthcare Development of the Republic of Kazakhstan

4. Experience with MCDA in the Russian Federation
Vlada Konstantinovna Fedyaeva, National Association of Experts on Rare Diseases (NAEREZ)